<DOC>
	<DOCNO>NCT02360774</DOCNO>
	<brief_summary>The purpose study investigate effect canagliflozin , medication approve FDA treatment type 2 diabetes , body weight metabolism people type 2 diabetes overweight obese . Canagliflozin lower glucose level blood make kidney excrete , rather absorb , glucose . Canagliflozin also often associated weight loss . The study population generally type 2 diabetic , age 18-75 year old , overweight obese .</brief_summary>
	<brief_title>Mechanisms Weight Loss With SGLT2 Inhibition</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>1 . Type 2 diabetes 2 . BMI 2545 kg/m2 3 . Hemoglobin A1C &gt; 6.5 % &lt; 9 % 4 . Normal renal function ( GFR &gt; 60 ) 5 . Age 1875 1 . Type 1 diabetes 2 . History recurrent UTI mycotic genital infection 3 . Treatment insulin GLP1 agent 4 . Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Canagliflozin</keyword>
	<keyword>Obesity</keyword>
	<keyword>Weight Loss</keyword>
	<keyword>Body Weight</keyword>
	<keyword>Body Weight Changes</keyword>
	<keyword>Overweight</keyword>
	<keyword>Sodium-glucose transporter subtype 2 inhibitor</keyword>
</DOC>